A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Meeting Abstract

  

Authors:	O'Brien, S. M.; Lamanna, N.; Kipps, T. J.; Flinn, I.; Zelenetz, A. D.; Burger, J. A.; Holes, L.; Johnson, D. M.; Gu, J.; Dansey, R. D.; Dubowy, R. L.; Coutre, S. E.
Abstract Title:	A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Meeting Title:	49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	31
Issue:	15 Suppl.
Meeting Dates:	2013 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2013-05-20
Language:	English
ACCESSION:	WOS:000335419602363
PROVIDER:	wos
DOI:	10.1200/jco.2013.31.15_suppl.7005
Notes:	Meeting Abstract: 7005 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/128748